TEV-53408 not checked
Teva Branded Pharmaceutical Products R&D LLC
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Vitiligo (2 trials), Celiac Disease
- Main trialPhase 2/3
- “The goal of these clinical trials is to learn if TEV-53408 can help adults with Non-Segmental Vitiligo (NSV). Vitiligo causes patches of skin to lose their color. The main questions the trials aim to answer are: Can TEV-53408 help bring color back to the skin on the face? Can TEV-53408 help bring color back to the skin on the body? What side effects may happen with TEV-53408? TEV-53408 will be compared with placebo to see if it helps bring color back to the skin. Participants will: Receive TEV-53408 or placebo as an injection under the skin Have their skin checked during the trials…”In the company’s words, NCT07920211 on ClinicalTrials.gov
Other drugs for Vitiligo
- RitlecitinibPfizer · Phase 3
- MH004Minghui Pharmaceutical (Hangzhou) Ltd · Phase 3
- UpadacitinibAbbVie · Phase 3
- Afamelanotide and NB-UVB LightClinuvel, Inc. · Phase 3
- LY4005130Eli Lilly · Phase 2
- D-2570InventisBio Co., Ltd · Phase 2
Coming up2
- 26 Apr 2028Phase 1 trial completes · ClinicalTrials.gov
- 12 Sep 2030Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | 12 Sep 2030 | Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo | |
| Phase 2Active, not recruiting | 2 Oct 2026 | A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease | |
| Phase 1Recruiting | 26 Apr 2028 | A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026